• 1
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  • 2
    Olivo-Marston SE, Mechanic LE, Mollerup S, et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis. 2010; 31: 1778-1786.
  • 3
    Navaratnam S, Murphy L, Qing G, et al. Estrogen receptor-beta (ER-beta) expression and non-small cell lung cancer (NSCLC) outcome [abstract]. J Clin Oncol. 2010; 28( suppl): Page. Abstract e21092.
  • 4
    Yan M, Chen X, Wang S, Li Y. Expression of ER and AR in lung cancer [in Chinese]. Zhongguo Fei Ai Za Zhi. 2008; 11: 126-129.
  • 5
    Chlebowski RT. Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol. 2009; 36: 566-571.
  • 6
    Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8: 1981-1997.
  • 7
    Joiner MC, Van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, ed. Basic Clinical Radiobiology. 2nd ed. New York: Oxford University Press; 1997: 106-112.
  • 8
    Vaupel P, Thews O, Mayer A, Hockel S, Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol. 2002; 178: 727-731.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 10
    Caglayan B, Fidan A, Salepci B, et al. Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer. Tuberk Toraks. 2004; 52: 323-332.
  • 11
    Hsu HC, Wang CJ, Huang EY, Sun LM. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. Br J Radiol. 2004; 77: 43-48.
  • 12
    Jaen Olasolo J, Alonso Redondo E, Leon Jiminez A, Rueda Ramos A. Non-small lung cancer. Survival after radiotherapy and prognostic factors [in Spanish]. Arch Bronconeumol. 2003; 39: 81-86.
  • 13
    Jeremic B, Milicic B, Dagovic A, Acimovic L, Milisavljevic S. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone. Int J Radiat Oncol Biol Phys. 2006; 65: 1112-1119.
  • 14
    Jeremic B, Milicic B, Acimovic L, Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol. 2005; 23: 6873-6880.
  • 15
    Jeremic B, Casas F, Wang L, Perin B. Radiation therapy for early stage (I/II) non-small cell lung cancer. Front Radiat Ther Oncol. 2010; 42: 87-93.
  • 16
    Hoyer M. Improved accuracy and outcome in radiotherapy of lung cancer. Radiother Oncol. 2008; 87: 1-2.
  • 17
    Munstedt K, Volzing M, Von Georgi R. Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep. 2004; 11: 711-717.
  • 18
    Rades D, Lang S, Schild SE, Alberti W. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol (R Coll Radiol). 2006; 18: 139-144.
  • 19
    Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2000; 46: 459-466.
  • 20
    Rudat V, Stadler P, Becker A, et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol. 2001; 177: 462-468.
  • 21
    Rudat V, Vanselow B, Wollensack P, et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol. 2000; 57: 31-37.